TW200640947A - Novel polypeptide ligands for toll-like receptor 2 (TLR2) - Google Patents

Novel polypeptide ligands for toll-like receptor 2 (TLR2)

Info

Publication number
TW200640947A
TW200640947A TW095103752A TW95103752A TW200640947A TW 200640947 A TW200640947 A TW 200640947A TW 095103752 A TW095103752 A TW 095103752A TW 95103752 A TW95103752 A TW 95103752A TW 200640947 A TW200640947 A TW 200640947A
Authority
TW
Taiwan
Prior art keywords
tlr2
novel polypeptide
toll
receptor
polypeptide ligands
Prior art date
Application number
TW095103752A
Other languages
English (en)
Inventor
Thomas J Powell
Yan Huang
Valerian Nakaar
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of TW200640947A publication Critical patent/TW200640947A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
TW095103752A 2005-01-31 2006-02-03 Novel polypeptide ligands for toll-like receptor 2 (TLR2) TW200640947A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64892305P 2005-01-31 2005-01-31

Publications (1)

Publication Number Publication Date
TW200640947A true TW200640947A (en) 2006-12-01

Family

ID=36777807

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095103752A TW200640947A (en) 2005-01-31 2006-02-03 Novel polypeptide ligands for toll-like receptor 2 (TLR2)

Country Status (6)

Country Link
US (1) US20090028889A1 (zh)
EP (2) EP2042186A1 (zh)
AR (1) AR052200A1 (zh)
CA (1) CA2596079A1 (zh)
TW (1) TW200640947A (zh)
WO (1) WO2006083792A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
ES2431327T3 (es) * 2005-10-28 2013-11-26 University Of Maryland, Baltimore Salmonella entérica serotipo Paratyphi A atenuada y usos de la misma
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2008013735A2 (en) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
WO2011084967A2 (en) * 2010-01-06 2011-07-14 Vaxinnate Corporation Methods and compositions for providing protective immunity in the elderly
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
WO2015011254A1 (en) 2013-07-26 2015-01-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US10439549B2 (en) * 2015-08-26 2019-10-08 Ravi Nagarajarao KURLAGUNDA Vehicle attached photovoltaic charging systems
GB201522618D0 (en) 2015-12-22 2016-02-03 Phoremost Ltd Methods of screening
US11931400B2 (en) 2017-03-07 2024-03-19 Psomagen, Inc. Therapeutic and diagnostics compositions targeting toll-like receptors and methods thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5227301A (en) 1989-11-03 1993-07-13 The 501 Institution For The Advancement Of Learning (Mcgill University) Immortalized bovine mannary epithelial cell line
AU5495500A (en) * 1999-06-16 2001-01-02 The Texas A & M University System Decorin binding protein essential peptides and methods of use
GB9927332D0 (en) * 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
GB0001704D0 (en) * 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
AU2001233114A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2001081581A2 (en) * 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20020061312A1 (en) 2000-07-31 2002-05-23 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AU2002365187A1 (en) * 2001-11-07 2003-07-24 Mannkind Corporation Epitope synchronization in antigen presenting cells
US20040180385A1 (en) * 2003-03-14 2004-09-16 Dooil Jeoung Method of diagnosing systemic lupus erythematosus

Also Published As

Publication number Publication date
EP2042186A1 (en) 2009-04-01
EP1853289A4 (en) 2008-04-09
CA2596079A1 (en) 2006-08-10
US20090028889A1 (en) 2009-01-29
AR052200A1 (es) 2007-03-07
EP1853289A2 (en) 2007-11-14
WO2006083792A2 (en) 2006-08-10
WO2006083792A3 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
TW200640947A (en) Novel polypeptide ligands for toll-like receptor 2 (TLR2)
WO2007053455A3 (en) Polypeptide ligans for toll-like receptor 4 (tlr4)
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
WO2018160754A3 (en) Inducible monovalent antigen binding protein
MX2021004660A (es) Moleculas de union multivalentes a base de igm- e iga-fc.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
WO2006083706A3 (en) Method to identify polypeptide toll-like receptor (tlr) ligands
IL245462A0 (en) Antagonists of human origin against cmet
MY154956A (en) Chimeric adenoviral vectors
ATE441007T1 (de) Bodenplatte mit verbindungsmitteln zur mechanischen verbindung und mit elastischen ausgleichmitteln
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
WO2008103947A3 (en) Activation of human antigen-presenting cells through clec-6
DE60334246D1 (de) Modulieren von immunantworten
WO2016172551A8 (en) METHODS OF IDENTIFYING BACTERIA COMPRISING BINDING POLYPEPTIDES
MX2021013657A (es) Conjugados de anticuerpo y farmaco.
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
MX2009003300A (es) Vectores de rhinovirus recombinantes.
WO2008103966A3 (en) Compositions and methods using toll-like receptors and unc93b
AR075195A1 (es) Un polipeptido (toxina a de clostridium chauvoei- ccta-) de clostridium chauvoei adn que codifica el polipeptido y una vacuna que comprende el polipeptido
WO2004083372A3 (en) Modulators of the notch signaling pathway immobilized on particles for modifying immune responses
MX2022014899A (es) Variantes y composiciones del lfa3 y sus usos.